BITEs: first-in-class bi-specific antibodies
Micromet’s BiTE (bi-specific T cell engager) antibody technology platform led to the creation of a clinical pipeline focused on new treatments for cancer and other conditions.
The lead product from the Micromet pipeline, BlincytoTM (Blinatumomab), was approved as a second-line treatment for relapsed or refractory acute lymphoblastic leukaemia.
CEO Christian Itin
Advent Contact Don Drakeman
Advent invested in 2001. Micromet listed on NASDAQ in 2006 (NASDAQ:MITI), and was acquired by Amgen for $1.16B in 2012.
Exited Investments
Amgen to Acquire Micromet
Press Release. Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies Micromet's Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types All-Cash Transaction…
Read More
Micromet’s Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin’s Lymphoma
Press Release. Durable responses ranging up to 30 months observed BETHESDA, Md., - Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1…
Read More
Micromet’s Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Press Release. German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease …
Read More
